CAPTRUST Financial Advisors’s Can-Fite BioPharma American Depositary Shares CANF Stock Holding History

CAPTRUST Financial Advisors’s Portfolio CANF Stock Details CANF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-569	Closed	-$7.04K	–	2754
2025 Q3	$7.04K	Hold	569	–	–	﹤0.01%	2618
2025 Q2	$11.9K	Buy	569 +37	+7%	+$852	﹤0.01%	2489
2025 Q1	$15.7K	Buy	+532	New	+$17K	﹤0.01%	2326
2022 Q3	–	Sell	-8	Closed	-$1K	–	2360
2022 Q2	$1K	Hold	8	–	–	﹤0.01%	4639
2022 Q1	$2K	Buy	+8	New	+$1.85K	﹤0.01%	4463

Other funds holding CANF

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

BWL

Bogart Wealth LLC Mclean, Virginia $2.92B AUM 23.85% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

CAM

Costello Asset Management Feasterville, Pennsylvania $333M AUM 25.99% 1-Year Est. Return

CAPTRUST Financial Advisors's CANF Position: Q4 2025 in Review

CAPTRUST Financial Advisors sold out of Can-Fite BioPharma American Depositary Shares (CANF) in Q4 2025, closing a stake of 569 shares — an estimated $7.04K sold.

CAPTRUST Financial Advisors first reported a position in CANF in Q1 2022 and held it in 5 quarters. The position peaked at $15.7K in Q1 2025. 15 funds tracked by Wall St. Rank hold CANF as of Q4 2025.

CAPTRUST Financial Advisors reported no remaining Can-Fite BioPharma American Depositary Shares position as of Q4 2025 after selling out during the quarter.
CAPTRUST Financial Advisors sold 569 Can-Fite BioPharma American Depositary Shares shares in Q4 2025, an estimated $7.04K.
CAPTRUST Financial Advisors first reported a position in Can-Fite BioPharma American Depositary Shares in Q1 2022 and held it in 5 quarters.
CAPTRUST Financial Advisors's Can-Fite BioPharma American Depositary Shares position peaked at $15.7K in Q1 2025.
15 funds tracked by Wall St. Rank held Can-Fite BioPharma American Depositary Shares as of Q4 2025.

Based on CAPTRUST Financial Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.